MILFORD, Mass. — June 15, 2017 – RenalGuard Solutions, Inc. today announced the appointment of J. Alex Martin, former President and Chief Executive Officer of Coherex Medical, as Chairman of the RenalGuard Board of Directors. Ethan Benovitz, remains as Vice-Chairman of the RenalGuard Board.

“Alex has 40 years of experience and leadership within the health care and medical device industries, that will serve our company well as we continue to grow and become a market leader in protecting patients from acute kidney injury,” said Ethan Benovitz, Vice-Chairman of RenalGuard Solutions. “His proven track record in leading high growth organizations will be invaluable to our company as we further expand our European sales and prepare to enter the U.S. market, as well as extend trials of RenalGuard® to new clinical indications.”

“I am very pleased to work with RenalGuard’s excellent management team and board to help realize the full value of the company’s approach and products,” said Mr. Martin. “I strongly support the company’s mission of offering technology that better enables patients with kidney problems to benefit from potentially lifesaving cardiac interventions. I believe that the RenalGuard technology will become a standard of care for patients at risk for procedure-related acute kidney injury.”

As the President, CEO and Director of Coherex Medical, Mr. Martin led the company to a successful exit with Biosense Webster, a Johnson and Johnson company, in November 2015. Prior to Coherex, he was the President and CEO of WorldHeart Corporation, where he led the company to an acquisition by HeartWare in August 2012. Previously, Mr. Martin has held senior leadership roles with Edwards Lifesciences, Cordis Corporation, a Johnson & Johnson Company, Cambridge Heart and C.R. Bard. Mr. Martin holds a bachelor’s degree from the University of Kentucky.

About RenalGuard Solutions, Inc.
RenalGuard Solutions, Inc. is a medical device company focused on innovative technologies for the cardiac and vascular markets. The company’s lead product, RenalGuard®, is designed to protect patients from acute kidney injury (AKI), including contrast-induced AKI. Investigator-sponsored studies in Europe have demonstrated RenalGuard’s effectiveness at preventing CI-AKI in at-risk patients. RenalGuard is CE-marked and is sold in Europe and certain countries around the world via a network of distributors. The CIN-RG RenalGuard pivotal study is underway in the United States to support a planned Premarket Approval filing with the U.S. Food and Drug Administration in 2018. For further information, please visit the company’s website at



Gregory Mann RenalGuard CFO 508-541-8800 For Media: Joan Kureczka Bioscribe, Inc. 415-821-2413

Download PDF